In Japan, where zonisamide has been prescribed for a longer period than in the United States, studies have shown that HLA‐A*02:07 may be a biomarker for susceptibility to zonisamide‐induced SJS/TEN 12. Here, HLA-A is linked to Schwartz-Jampel syndrome.